» Articles » PMID: 24343214

Disease Burden and Treatment Adherence in Psoriasis Patients

Overview
Journal Cutis
Specialty Dermatology
Date 2013 Dec 18
PMID 24343214
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Psoriasis can have a large impact on a patient's quality of life, yet adherence to psoriasis treatment often is poor. A large international study was conducted in adults with psoriasis and/or psoriatic arthritis to characterize the disease burden of psoriasis and its relationship to treatment adherence using a detailed, self-administered questionnaire. The results presented in this article represent the subset of US respondents who were currently taking prescription medication (N=193). The impact of psoriasis was graded as moderate to extremely high by 71% of US survey respondents. Among the respondents who did not adhere to prescribed treatments, approximately 50% attributed their nonadherence to forgetfulness and reported using the medication when they deemed it necessary. Respondents expressed a strong willingness to adhere to medications that were effective and to try multiple new treatments to find an optimal therapy. Of the respondents who were currently taking prescription medication, 88% were using topical therapies. The greatest unmet needs associated with topical psoriasis treatment were identified as fewer side effects, more rapid onset of action, and increased efficacy. The majority of respondents described positive relationships with their physician and a positive outlook with regard to physician communication, indicating an opportunity for the physician to directly influence patients' perceptions of disease burden and quality of life. When treating psoriasis with topical therapies, physicians should focus on improving and maintaining patients' quality of life, as this practice can be expected to improve treatment adherence and efficacy.

Citing Articles

A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of , in adults with mild-to-moderate plaque psoriasis.

Ehst B, Strober B, Blauvelt A, Maslin D, Macaro D, Carpenter N Front Med (Lausanne). 2024; 11:1292406.

PMID: 38813388 PMC: 11133679. DOI: 10.3389/fmed.2024.1292406.


A narrative review of fixed combination calcipotriol/betamethasone aerosol foam (Enstilar) in the management of psoriasis with scalp involvement.

Staubach P, Korber A, Trueb R, Mann C, von Kiedrowski R Drugs Context. 2024; 13.

PMID: 38770372 PMC: 11104291. DOI: 10.7573/dic.2024-1-6.


Recommendations for Initiating Systemic Therapy in Patients with Psoriasis.

Martin G, Young M, Aldredge L J Clin Aesthet Dermatol. 2019; 12(4):13-26.

PMID: 31119006 PMC: 6508485.


A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience.

van den Bemt B, Gettings L, Domanska B, Bruggraber R, Mountian I, Kristensen L Drug Deliv. 2019; 26(1):384-392.

PMID: 30905213 PMC: 6442222. DOI: 10.1080/10717544.2019.1587043.


Can an app supporting psoriasis patients improve adherence to topical treatment? A single-blind randomized controlled trial.

Svendsen M, Andersen F, Andersen K, Andersen K BMC Dermatol. 2018; 18(1):2.

PMID: 29415699 PMC: 5804085. DOI: 10.1186/s12895-018-0071-3.